SCHEMBL7380720

SCHEMBL7380720

CC(C)(C)OC(=O)Nc1cccc(CCCC(=O)O)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLS O94925 4/20 0.41
NR3C2 P08235 1/20 0.40
CCR2 P41597 1/20 0.39
ITGAV P06756 4/20 0.38
ITGB6 P18564 1/20 0.38
ITGB3 P05106 3/20 0.37
ITGB5 P18084 3/20 0.37
ITGB1 P05556 2/20 0.37
ITGA5 P08648 2/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
GAA P10253 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
PDE5A O76074 1/20 0.37
LCK P06239 1/20 0.37
SCN9A Q15858 1/20 0.37
MAPK8 P45983 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7372453 0.86 GLS (0.44) GLSNR3C2CCR2LCKSCN9A
SCHEMBL4715049 0.86 NR3C2 (0.44) GLSNR3C2CCR2LCKSCN9A
SCHEMBL3427899 0.84 PDE5A (0.50) GLSNR3C2CCR2MEN1NPC1
SCHEMBL6320838 0.84 NR3C2 (0.43) GLSNR3C2CCR2MEN1NPC1
SCHEMBL23649504 0.84 NR3C2 (0.44) GLSNR3C2CCR2NPC1RAB9A
SCHEMBL30041417 0.84 NR3C2 (0.44) GLSNR3C2CCR2NPC1RAB9A
SCHEMBL6492788 0.83 NR3C2 (0.45) GLSNR3C2CCR2LCKSCN9A
SCHEMBL29988292 0.83 GLS (0.42) GLSNR3C2CCR2MEN1NPC1
SCHEMBL1022260 0.83 GLS (0.42) GLSNR3C2CCR2MEN1NPC1
Hydrochloric Acid SCHEMBL28586309 0.82 NR3C2 (0.44) GLSNR3C2CCR2LCKSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6294549-B1 COMPOUNDS USEFUL FOR INHIBITING RESTENOSIS, ANGIOGENESIS, ATHEROSCLEROSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, INFLAMMATION OR TUMOR GROWTH. MERCK & CO., INC. 2001-09-25 US disclosed
US-5952306-A INHIBITING THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS AND INHIBITING THE AGGREGATION OF BLOOD PLATELETS; INHIBITING OSTEOCLAST CELLULAR ADHESION TO BONE SURFACES MERCK & CO., INC. (US) 1999-09-14 US disclosed
EP-0880511-A4 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1999-06-16 EP disclosed
EP-0880511-A1 INTEGRIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1998-12-02 EP disclosed
WO-1997026250-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1997-07-24 WO disclosed